ストックスクリーナーアプリを入手
295.77
0.74%
-2.75
前日終値:
$298.52
開ける：
$297.21
24時間の取引高:
210.54K
Relative Volume:
0.56
時価総額：
$32.45B
収益：
$3.81B
当期純損益:
$-644.79M
株価収益率:
-47.40
EPS:
-6.24
ネットキャッシュフロー:
$-669.77M
1週間 パフォーマンス:
-1.60%
1か月 パフォーマンス:
+22.95%
6か月 パフォーマンス:
+32.57%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$293.90
$297.90
1週間の範囲:
$287.00
$313.29
52週間の値動き範囲:
$172.67
$313.29
Beone Medicines Ltd Adr Stock (ONC) Company Profile
名前
Beone Medicines Ltd Adr
セクター
電話
13459494123
住所
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
296.12 | 33.25B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
382.37 | 96.11B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.82 | 60.40B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.12 | 54.91B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
670.49 | 41.30B | 3.05B | 1.28B | -614.78M | 19.58 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-03-03 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-12-03 | 再開されました | Morgan Stanley | Overweight |
| 2024-09-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-02-06 | 再開されました | JP Morgan | Overweight |
| 2023-09-12 | 開始されました | Macquarie | Outperform |
| 2023-08-17 | 開始されました | Jefferies | Buy |
| 2023-07-17 | 開始されました | Citigroup | Buy |
| 2023-06-30 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 開始されました | Daiwa Securities | Buy |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-10-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 再開されました | JP Morgan | Overweight |
| 2022-03-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 開始されました | Deutsche Bank | Buy |
| 2021-10-12 | 開始されました | Bernstein | Outperform |
| 2021-10-06 | アップグレード | CLSA | Underperform → Buy |
| 2021-03-08 | 開始されました | China Renaissance | Buy |
| 2021-03-01 | ダウングレード | CLSA | Outperform → Underperform |
| 2020-11-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | ダウングレード | Maxim Group | Buy → Hold |
| 2020-11-06 | ダウングレード | Piper Sandler | Neutral → Underweight |
すべてを表示
Beone Medicines Ltd Adr (ONC) 最新ニュース
Insider Selling: BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) CFO Sells 1,190 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Hits New 52-Week HighHere's Why - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Buy" by Analysts - MarketBeat
BeOne Medicines DRC earnings missed by $0.04, revenue topped estimates - Investing.com India
Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) PT at $327.56 - Defense World
Chan Henry Lee Sells 920 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month HighHere's What Happened - MarketBeat
Lai Wang Sells 259 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines stock hits 52-week high at 304.0 USD - Investing.com India
Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End - Ariva
BeOne Medicines stock rises after positive EU opinion for lung cancer drug - Investing.com India
Lai Wang Sells 700 Shares of BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Stock - MarketBeat
Stevanato (STVN) Soars 10.0%: Is Further Upside Left in the Stock? - Yahoo Finance
BeOne Medicines (NASDAQ:ONC) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
BeOne Medicines (NASDAQ:ONC) Reaches New 52-Week High Following Analyst Upgrade - Defense World
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 - GlobeNewswire Inc.
BeOne Medicines (NASDAQ:ONC) Shares Gap UpTime to Buy? - MarketBeat
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO Sells $7,044,470.76 in Stock - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Rating of “Buy” from Brokerages - Defense World
AFC Gamma (NASDAQ:AFCG) Shares Down 4.9% – What’s Next? - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines (NASDAQ:ONC) Stock Price Down 3.6% Following Insider Selling - MarketBeat
BeOne Medicines (NASDAQ:ONC) Receives “Outperform” Rating from Royal Bank Of Canada - Defense World
BeOne Medicines stock rating reiterated at Outperform by RBC Capital - Investing.com
BeOne Medicines (NASDAQ:ONC) Stock Price Down 5.4%Here's What Happened - MarketBeat
Entergy Corp’s Shares Reel: 0.54% Quarterly Revenue Decline Amid 35.88B Market Cap - investchronicle.com
BeOne Medicines Ltd ADR (ONC) Stock: Uncovering 52-Week Market Trends - investchronicle.com
Cancer Stock Vaults 40% As Clinical Trial Shows 'Promise'; Sales Reach $1 Billion, Earnings To Triple - Investor's Business Daily
LLY Stock Quote Price and Forecast - CNN
H.C. Wainwright maintains neutral rating on Zymeworks stock - Investing.com India
China approves novel HER2-targeted therapy for BTC By Investing.com - Investing.com South Africa
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge By Stocktwits - Investing.com India
China approves novel HER2-targeted therapy for BTC - Investing.com Australia
BeiGene completes corporate re-domiciliation to Switzerland - Investing.com
BeiGene completes corporate re-domiciliation to Switzerland By Investing.com - Investing.com Nigeria
Beone Medicines Ltd Adr (ONC) 財務データ
収益
当期純利益
現金流量
EPS
1.45%
0.55%
大文字化:
|
ボリューム (24 時間):